Haiou Qin focuses her life sciences practice on patent strategies, filings, prosecution, Hatch-Waxman litigation, inter partes reviews, and due diligence. Utilizing her scientific background, she has deep subject matter knowledge across multiple modalities of therapeutics, including small molecules, bispecific antibodies, chimeric degraders / PROTACs, siRNAs, and cell therapies.

Haiou’s experience includes conducting FTO analyses and patent filings covering varieties of subject matters, including compositions of matter, methods of treatment, formulations, delivery systems, and combination therapies. In addition, she has extensive IP due diligence and transaction experience covering license, MTA, research collaboration, product supply, and service agreements.

Having formerly worked in-house, Haiou relates to her clients and works closely with them to help accomplish their business goals. Prior to joining Wolf Greenfield, Haiou served as Senior Patent Counsel for Johnson and Johnson, where she provided cross-border legal support and counseling. Prior to that, Haiou practiced at an intellectual property law firm and a full-service international law firm.



  • Co-authored, Claiming Priority in the Area of Pharmaceuticals in View of Some Representative Cases, Journal of Law Applications, 18:131-138 (2018)
  • Co-authored, An Overview of Motions to Amend in U.S. Inter Partes Reviews, China Intellectual Property News, May 22, 2017
  • Co-authored, The Balance of Copyright Protection and Technology Development, China Patents and Trademarks, January 16, 2017
  • Authored, Paragraph IV Challenges: OxyContin Case Study, Chinese Pharmaceutical Enterprises Association, September 1, 2016
  • Co-authored, A Study on Examination Standards of Patentability in the U.S., Chinese Intellectual Property Magazine, 6:116-118 (2016)


Expand All

Haiou Qin focuses her life sciences practice on patent strategies, filings, prosecution, Hatch-Waxman litigation, inter partes reviews, and due diligence. Utilizing her scientific background, she has deep subject matter knowledge across multiple modalities of therapeutics, including small molecules, bispecific antibodies, chimeric degraders / PROTACs, siRNAs, and cell therapies.

Haiou’s experience includes conducting FTO analyses and patent filings covering varieties of subject matters, including compositions of matter, methods of treatment, formulations, delivery systems, and combination therapies. In addition, she has extensive IP due diligence and transaction experience covering license, MTA, research collaboration, product supply, and service agreements.

Having formerly worked in-house, Haiou relates to her clients and works closely with them to help accomplish their business goals. Prior to joining Wolf Greenfield, Haiou served as Senior Patent Counsel for Johnson and Johnson, where she provided cross-border legal support and counseling. Prior to that, Haiou practiced at an intellectual property law firm and a full-service international law firm.

  • Co-authored, Claiming Priority in the Area of Pharmaceuticals in View of Some Representative Cases, Journal of Law Applications, 18:131-138 (2018)
  • Co-authored, An Overview of Motions to Amend in U.S. Inter Partes Reviews, China Intellectual Property News, May 22, 2017
  • Co-authored, The Balance of Copyright Protection and Technology Development, China Patents and Trademarks, January 16, 2017
  • Authored, Paragraph IV Challenges: OxyContin Case Study, Chinese Pharmaceutical Enterprises Association, September 1, 2016
  • Co-authored, A Study on Examination Standards of Patentability in the U.S., Chinese Intellectual Property Magazine, 6:116-118 (2016)